Article

AHAF launches 'See A Better Tomorrow' campaign

The American Health Assistance Foundation (AHAF) has launched “See A Better Tomorrow,” a public education campaign that encourages people to schedule comprehensive eye exams to help protect against irreversible vision loss caused by glaucoma or age-related macular degeneration (AMD).

Clarksburg, MD-The American Health Assistance Foundation (AHAF) has launched “See A Better Tomorrow,” a public education campaign that encourages people to schedule comprehensive eye exams to help protect against irreversible vision loss caused by glaucoma or age-related macular degeneration (AMD).

AHAF attests that early diagnosis is key to limiting or preventing vision loss from these two degenerative diseases, which affect 16 million Americans.

“Many people are unaware that they have these diseases until they start to experience symptoms, after irreversible vision loss may have occurred,” said AHAF president and chief executive officer Stacy Pagos Haller. “The good news is that with detection and treatment, eye doctors can often slow or stop the progression of these diseases and help protect against blindness.”

Through public service announcements and a wide range of resources, AHAF’s campaign asks people to visualize places or people they want to see, and then to protect their ability to continue seeing them by having an eye exam. For more information on the multi-platform campaign, visit www.ahaf.org/seeabettertomorrow.

AHAF is a nonprofit organization dedicated to finding cures for age-related degenerative diseases by funding research worldwide under its three program areas: Alzheimer’s disease research, macular degeneration research, and national glaucoma research (www.ahaf.org). To date, AHAF’s macular degeneration research and national glaucoma research programs have provided more than $31.5 million in grants to identify new prevention, diagnostic, and treatment options for people facing vision loss.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.